The introduction of "highly sensitive" cardiac troponin assays (hsTn) has reinforced the evidence that only serial testing incorporated in running algorithms allows a more accurate diagnosis of acute myocardial infarction. In this report, we consider the available evidence supporting the use of fast track protocols for ruling out and ruling in non-ST elevation myocardial infarction (NSTEMI) and compare it with the content of recently released guideline by the European Society of Cardiology, noting some uncomfortable aspects that need urgent clarification and/or revision. Firstly, the guideline drafters have to reconsider the available evidence that does not permit to assign the same class and level of evidence to the very well-validated 0-3 h algorithm and to the 0-1 h algorithm. In agreement with the validity of available data, the limitations of fast track protocols, in particular of the 0-1 h algorithm for NSTEMI rule-in, calls for caution. Secondly, as the current diagnostics guidance by the UK National Institute for Health and Care Excellence recommends, rapid diagnostic protocols should be performed only using well-validated hsTn; recommending the use of an assay before being commercially available is not fair and scientifically sound.
Introduction
The current diagnostics guidance by the UK National Institute for Health and Care Excellence (NICE) recommends the use of "highly sensitive" cardiac troponin assays (hsTn) for the early rule out of non-ST elevation acute myocardial infarction (NSTEMI) in people presenting to an Emergency Department (ED) with chest pain and suspected acute coronary syndrome (ACS) [1] . It is important to note that, although some end-users may believe that several commercial troponin assays may fulfil the hsTn criteria, the mentioned recommendation reports an explicit reference to Roche Diagnostics Elecsys hsTn T and Abbott Diagnostics Architect hsTn I, the only two commercially available hsTn assays with enough scientific evidence behind.
In spite of the 2014 NICE guidance, the hsTn availability has often not been welcomed by clinicians, claiming an increase in false-positive results, and it is now clear that the hsTn introduction requires changes to diagnostic rules and algorithms [2] . The improved sensitivity of hsTn has reinforced the evidence that the 99th percentile decision limit, if applied to only one result, is not functional to the diagnosis of acute myocardial infarction (AMI) and only serial testing allows for the discrimination of acute from chronic pathophysiological mechanisms of troponin release. This is supported by the evidence of high interindividual biological variability of cardiac troponin, jeopardising the clinical application of any fixed cut-off value, as well as by the proof of a wide disagreement between hsTn methods to identify patients above the 99th percentile cut-off [2] [3] [4] . Sound evidence currently fosters to characterise temporal patterns describing hsTn variation between consecutive samples in one patient, with the final aim to dichotomise typical/atypical hsTn curves according to the magnitude of troponin changes and characterise patterns typical for acute myocardial necrosis [2] . A recent international survey has however, shown a wide misfit between the application of serial testing approach, performed in 70% of audited laboratories, and the definition of a significant hsTn trend (i.e. the δ change) for typical curves, missing in 64% of cases [5] . According to Biener et al. [6] , in patients presenting at ED, using hsTn T the highest capability to discriminate NSTEMI from non-ACS is achieved by adding a δ value of >53% as decisional criterion to the 99th percentile cut-off applied to the admission value. Thus, hsTn changes in values over serial measurements, joined to baseline concentrations, incorporated in running algorithms allow more accurate AMI diagnostics [7] .
The 0-3 h hsTn protocol to rule-out and rule-in AMI
Moving from the conventional troponin assays to hsTn has entailed to detect a typical increase within 3 h from admission with a 100% sensitivity for NSTEMI diagnosis and a net diagnostic gain of 3-9 h [2, 8] . Notably, in an ad hoc study the diagnostic anticipation associated to the 0-3 h hsTn testing protocol resulted in a cost for total qualityadjusted life years gained ~4-fold lower than that related to delayed (10 h) testing protocol using conventional troponin assay [9] . This evidence has been central for incorporating a recommendation for the 0-3 h rapid ACS rule-out protocol using hsTn in the 2011 European Society of Cardiology (ESC) guidelines [10] and, 1 year later, to support a rapid 0-3 h AMI rule-in approach [11] .
Although the 0-3 h protocol application may have an undisputable positive impact on clinical practice, some limitations have been highlighted. As nicely reported by Pickering et al. [12] , clinicians should have confidence that this algorithm can be used to correctly diagnose a substantial proportion of patients, but its predictive values (PV) are probably suboptimal both for rule-in (positive PV, ~85%) and rule-out (negative PV, ~90%) patients. Particularly, they argued that even two successive hsTn values below the 99th percentile limit should not be used to rule-out AMI.
Rapid rule-out of AMI using undetectable concentrations of hsTn at admission Emergency medicine is constantly seeking more rapid but still safe ACS ruling-out processes. In particular, ED physicians consider that the minimum standard for the accuracy of a ruling-out discharge pathway for chest pain patients should be at least 99% negative PV [13] . Considering a diagnostic strategy including only hsTn determination at patient admission, a negative PV >99% can be reached when the diagnostic sensitivity is close to 100%. This is achievable by setting the limit of blank (LOB) (defined as the highest measurement result that is likely to be observed for a sample that contains no troponin ['blank sample']) [14] of hsTn as decision threshold, even if some studies have proposed as an alternative the hsTn limit of detection (LOD) (defined as the lowest amount of troponin in a biological sample that can reliably be detected by that method) as rule-out cut-off, but without any substantial difference in diagnostic performance [15] [16] [17] [18] [19] . However, if by applying the hsTn LOB (or LOD) cut-off at admission only less than one patient with NSTEMI in 100 consecutive ED patients is missed, an undetectable hsTn value in patients admitted to ED with chest pain is relatively rare, and thus a very early rule-out may concern only a minority of subjects presenting to the ED with a paltry effect on the workload. Furthermore, we might doubt on the total safety of this approach as undetectable hsTn at admission may also characterise patients suffering of unstable angina and thus it does not necessarily mean patient discharge.
The 0-1 h hsTn protocol to rule-out (and rule-in) AMI
To try to reach an acceptable compromise for quickly ruling out and ruling in AMI, diagnostic algorithms using two serial hsTn measurements at ED presentation and after 1 h have been proposed and prospectively validated only for hsTn T [20] [21] [22] . Accordingly, AMI could be excluded with a negative PV >99% if the admission hsTn T value is <12 ng/L and the absolute 0-1 h δ change is <3 ng/L. On the other hand, patients with baseline hsTn T values ≥52 ng/L or absolute 0-1 h δ change ≥5 ng/L have a probability to have AMI ~75%. The remaining patients in the so-called "observational zone" (corresponding to 22%-23% of tested subjects) should remain under observation, further resulting in a prevalence of AMI of 22% [21] .
Concerns related to the practicability of 0-1 h algorithm have been raised. First, a low proportion of enrolled patients presenting to ED with an early onset of symptoms (<3 h) as well as the observational design of the validation study, with no control arm, seem the main threatens to the reliability and inference of obtained results [23] . Notably, in patients with an early onset of symptoms the 0-1 h algorithm criteria may fail as a hsTn change could occurs later [24] . By applying this algorithm to patients with symptom onset <3 h or an admission hsTn T value <LOD to those presenting later, Pickering et al. [25] recently showed an insufficient sensitivity (~97%) to confidently discharge this type of patients. When applying an analogous algorithm using Abbott hsTn I, similar results (i.e. sensitivity of 98.8%) were obtained [25] . On the other hand, both hsTn T and I 0-1 h algorithms exhibited far modest positive PV (63.4 and 68.1%, respectively) to assure an effective rule-in [25] . It has been noted that the design of current studies is probably more appropriate to evaluate the algorithm performance for ruling out NSTEMI and not for ruling in, which represents a more complex clinical decision, lacking proven benefit of an immediate intervention for most patients [24] .
As far as the algorithms <3 h are considered, the time of blood collection became progressively more important and so this time should be recorded with accuracy. In several healthcare settings, the second sample at 1 h could be collected from patients with chest pain before clinicians are able to know the result of hsTn value of sample collected at ED admission. The mentioned clinical trials were performed in highly qualified university and research institutions and patients enrolled in these studies can be different from patients presenting to ED in district or rural hospitals (more often older and with more co-morbidities than those enrolled in clinical trials).
It sounds also difficult accurately reproducing locally in daily practice the suggested δ criteria involving a very small hsTn variation that in original studies was obtained with centralised and very well-controlled measurements. Finally, the use of the generalised 99th percentile cut-off instead of thresholds partitioned for gender was hypothesised unpredictably misclassifying AMI in males and females [26] . In reply to this criticism, in a sub-analysis of the original study the authors estimated the impact of the use of gender-specific cut-offs compared to the single 99th percentile hsTn T cut-off on diagnosis and prognosis of AMI [27] . They did not observe any relevant benefit on outcomes by reclassification according to gender-specific cut-offs and in females the reclassification even resulted in a negative impact on outcomes as assessed with net reclassification improvement approach. In particular, the use of gender-specific cut-offs was shown in females to potentially increase "false positive" results and the misclassification in ACS and non-ACS, leading to an overdiagnosis of AMI and overuse of extensive diagnostic testing [27] .
Summarising the implications of diagnostic accuracy of 0-1 h algorithm according to the available evidence, we can argue that this approach could be effective for ruling out NSTEMI, with similar negative PV of the LOB/ LOD cut-off use at admission [but effective on a higher percentage (~60%) of subjects admitted to ED with chest pain], but very limited for ruling in. Adding patient history (no high risk) and electrocardiographic findings (nonischemic changes) may further improve the accuracy of the 0-1 h algorithm to rule-out AMI. This "extended algorithm" has resulted in the rule-out cohort in an incidence of major adverse cardiac events (MACE) at 30 days of 0.5%, becoming 0% when unstable angina was excluded from MACE [28] . In the future, an even lower MACE rate could be obtained by combining the 0-1 h algorithm ruleout power with clinical risk scores, such as HEART [29] . Clearly, to support the safety and the ultimate use of the 0-1 h algorithm and its extensions for ruling out NSTEMI in ED patients, a prospective validation in a broader population is warranted. Nevertheless, the 0-1 h algorithm has recently been recommended in ESC guidelines for the rapid rule-out and rule-in of NSTEMI in ED patients (a level 1B recommendation) [30] .
Other proposals to improve early AMI rule-in
A 0-2 h version of the previously discussed algorithm has also been proposed, but the negative PV for ruling out chest pain patients did not significantly change when compared to that obtained with the 0-1 h version [31, 32] . Conversely, the positive PV increased from 75% to 82%-85% tending to reach the value obtainable with the 0-3 h protocol, which is, however, considered suboptimal for AMI rule-in [12] .
In general, the attempts to improve the AMI rule-in pathway should account for the relationship between troponin concentrations detected at patient presentation and possible causes of troponin elevation. In other words, the probability of diagnosing AMI significantly increases with the entity of the hsTn elevation at admission. If values up to 7-8 times the 99th percentile limit are likely to be found in a wide array of non-cardiac causes in addition to small AMI, higher values in the vast majority of cases (>90%) will point out to AMI, the main differential diagnoses being severe myocarditis and tako-tsubo cardiomyopathy (Figure 1) . Data from the TRAPID-AMI population have shown that while the positive PV for NSTEMI is <50% in patients with hsTn T values at admission >99th percentile limit, it rapidly increases with the increase of troponin concentrations, resulting >85% for hsTn T > 100 ng/L [34] . Consequently, serial hsTn sampling may not be required for prediction of NSTEMI diagnosis in chest pain patients with markedly abnormal concentrations at presentation. Integrating this information in the originally proposed rapid algorithm [2] may therefore further improve its performance (Figure 2 ).
hsTn turnaround time: a neglected issue
The implementation of fast track hsTn protocols, whatever previously described option is selected, is conditional on laboratories meeting clinically appropriate turnaround time (TAT) for reporting results of hsTn tests to clinical wards, otherwise all clinical benefits of these approaches should be lost. This is also vital because both so far validated hsTn methods (i.e. Roche and Abbott) are not available as point-of-care measurements and the point-of-care troponin assays on the market lack sensitivity. ESC guidelines recommend 1 h as maximum TAT to allow a safe intervention and a favourable outcome in patients with NSTEMI [10, 30] . Marked improvement in TAT is obtainable by introducing pneumatic tube transportation and computerised patient order entry management [35] . In our academic hospital, the hsTn test exploits both tools combining them with a dedicated path, enabling rapid The above values represent initial hsTnT concentrations (Cobas e411, Roche Diagnostics) on suspected acute coronary syndrome (ACS) patients admitted to the Emergency Department (ED). The question mark after "Appropriate treatment" when the admission hsTnT is 16-54 ng/L and δ changes >50% means that at present there are no data which would prove that patients with NSTEMI may always benefit from an immediate intervention as shown for patients with ST-elevation AMI. Note that the procedure reported in the figure is only an example and that it is validated only for the academic hospital of the authors and only for the method for hsTnT used in their laboratory. AMI, acute myocardial infarction; NPV, negative predictive value; NSTEMI, non-ST elevation myocardial infarction; PPV, positive predictive value. As hsTn concentrations are method-dependent, for exemplification numbers relate to hsTnT. AMI, acute myocardial infarction; PE, pulmonary embolism; AHF, acute heart failure; CAD, coronary artery disease; CHF, chronic heart failure. Adapted from [33] . management of samples in the pre-analytical phase as well as quick availability of hsTn results employing autovalidation rules. This working strategy ensures an average TAT of 31 min (90th percentile at 44 min), widely fulfilling the ESC recommended goal [36] .
Concluding remarks
Considering the available evidence (briefly summarised in this report) and comparing it with the recently released ESC guidelines for the management of ACS in patients presenting without persistent ST-segment elevation [30] , we note some uncomfortable aspects that need urgent clarification and/or revision. Firstly, the inequality between "sensitive" and "high-sensitive" assays (both recommended in the ESC guidelines) should be thoroughly considered, as rapid diagnostic protocols can be performed only using hsTn (read Roche or Abbott, according to the NICE systematic review) [1] . Secondly, the guideline drafters have to reconsider the available evidence that does not permit to assign the same class and level of evidence (IB) to the quite well validated 0-3 h algorithm (by the way, recommended only for rapid rule-out) and to the 0-1 h algorithm (recommended both for rule-out and rule-in). Finally, recommending the use of an hsTn before being commercially available (i.e. Dimension Vista) [30] , with the evidence based on just one paper authored by some extensors of the ESC guidelines [37] , is not fair and scientifically sound [38, 39] . In agreement with the validity of available data, the limitations of fast track protocols, in particular of the 0-1 h algorithm for NSTEMI rule-in, call for caution.
Other authors have recently discussed the main limitations of studies supporting the evidence for recommending fast track algorithms in 2015 ESC guidelines [40, 41] . Our remarks on the formulated recommendations add further caveats to be considered in their clinical application. What is probably innovative and noteworthy in using repeated close measures of hsTn is the early partition of patients into three groups (rule-out, observe, and rule-in) that allows to quickly move forward with different management strategies. For instance, non-invasive imaging procedures could be concentrated on the "observe" patients, typically including elderly men with pre-existing coronary artery disease and other non-cardiac complications [42] .
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